The p16INK4a–RB pathway plays a critical role in preventing inappropriate cell proliferation and is often targeted by viral oncoproteins during immortalization. Latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is often present in EBV-associated proliferative diseases and is critical for the immortalizing and transforming activity of EBV. Unlike other DNA tumor virus oncoproteins, which possess immortalizing activity, LMP1 does not bind to retinoblastoma tumor suppressor protein, but instead blocks the expression of p16INK4a tumor suppressor gene. However, it has been unclear how LMP1 represses the p16INK4a gene expression. Here, we report that LMP1 promotes the CRM1-dependent nuclear export of Ets2, which is an important transcription factor for p16INK4a gene expression, thereby reducing the level of p16INK4a expression. We further demonstrate that LMP1 also blocks the function of E2F4 and E2F5 (E2F4/5) transcription factors through promoting their nuclear export in a CRM1-dependent manner. As E2F4/5 are essential downstream mediators for a p16INK4a-induced cell cycle arrest, these results indicate that the action of LMP1 on nuclear export has two effects on the p16INK4a–RB pathway: (1) repression of p16INK4a expression and (2) blocking the downstream mediator of the p16INK4a–RB pathway. These results reveal a novel activity of LMP1 and increase an understanding of how viral oncoproteins perturb the p16INK4a–RB pathway.
Skip Nav Destination
Article navigation
21 July 2003
Article|
July 08 2003
Epstein-Barr virus LMP1 blocks p16INK4a–RB pathway by promoting nuclear export of E2F4/5
Naoko Ohtani,
Naoko Ohtani
1Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK
Search for other works by this author on:
Paul Brennan,
Paul Brennan
2Section of Infection and Immunity, University of Wales College of Medicine, Cardiff CF4 4XX, UK
Search for other works by this author on:
Stefan Gaubatz,
Stefan Gaubatz
3Institute for Molecular Biology and Tumor Research, Philipps-University Marburg, 35037 Marburg, Germany
Search for other works by this author on:
Elaine Sanij,
Elaine Sanij
4Centre for Functional Genomics and Human Disease, Monash Institute of Reproduction and Development, Monash University, Clayton, Victoria 3800, Australia
Search for other works by this author on:
Paul Hertzog,
Paul Hertzog
4Centre for Functional Genomics and Human Disease, Monash Institute of Reproduction and Development, Monash University, Clayton, Victoria 3800, Australia
Search for other works by this author on:
Ernst Wolvetang,
Ernst Wolvetang
4Centre for Functional Genomics and Human Disease, Monash Institute of Reproduction and Development, Monash University, Clayton, Victoria 3800, Australia
Search for other works by this author on:
Jacques Ghysdael,
Jacques Ghysdael
5CNRS UMR 146, Institut Curie Centre Universitaire, bat 110 91405 Orsay, France
Search for other works by this author on:
Martin Rowe,
Martin Rowe
2Section of Infection and Immunity, University of Wales College of Medicine, Cardiff CF4 4XX, UK
Search for other works by this author on:
Eiji Hara
Eiji Hara
1Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK
6Division of Protein Information, Institute for Genome Research, University of Tokushima, Tokushima 770-8503, Japan
Search for other works by this author on:
Naoko Ohtani
1Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK
Paul Brennan
2Section of Infection and Immunity, University of Wales College of Medicine, Cardiff CF4 4XX, UK
Stefan Gaubatz
3Institute for Molecular Biology and Tumor Research, Philipps-University Marburg, 35037 Marburg, Germany
Elaine Sanij
4Centre for Functional Genomics and Human Disease, Monash Institute of Reproduction and Development, Monash University, Clayton, Victoria 3800, Australia
Paul Hertzog
4Centre for Functional Genomics and Human Disease, Monash Institute of Reproduction and Development, Monash University, Clayton, Victoria 3800, Australia
Ernst Wolvetang
4Centre for Functional Genomics and Human Disease, Monash Institute of Reproduction and Development, Monash University, Clayton, Victoria 3800, Australia
Jacques Ghysdael
5CNRS UMR 146, Institut Curie Centre Universitaire, bat 110 91405 Orsay, France
Martin Rowe
2Section of Infection and Immunity, University of Wales College of Medicine, Cardiff CF4 4XX, UK
Eiji Hara
1Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK
6Division of Protein Information, Institute for Genome Research, University of Tokushima, Tokushima 770-8503, Japan
Address correspondence to Eiji Hara, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK. Tel.: 44-161-446-3122. Fax: 44-161-446-3075. E-mail: [email protected]
*
Abbreviations used in this paper: ChIP, chromatin-immunoprecipitation; E2F4/5, E2F4 and E2F5; EBV, Epstein-Barr virus; HDF, human diploid fibroblast; LMB, leptomycin B; LMP1, latent membrane protein 1; MEF, mouse embryonic fibroblast; MEK, MAPK/ERK kinase; NES, nuclear export signal; pRB, retinoblastoma tumor suppressor protein.
Received:
February 14 2003
Revision Received:
May 08 2003
Accepted:
June 03 2003
Online ISSN: 1540-8140
Print ISSN: 0021-9525
The Rockefeller University Press
2003
J Cell Biol (2003) 162 (2): 173–183.
Article history
Received:
February 14 2003
Revision Received:
May 08 2003
Accepted:
June 03 2003
Citation
Naoko Ohtani, Paul Brennan, Stefan Gaubatz, Elaine Sanij, Paul Hertzog, Ernst Wolvetang, Jacques Ghysdael, Martin Rowe, Eiji Hara; Epstein-Barr virus LMP1 blocks p16INK4a–RB pathway by promoting nuclear export of E2F4/5 . J Cell Biol 21 July 2003; 162 (2): 173–183. doi: https://doi.org/10.1083/jcb.200302085
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement
Advertisement